More than Just a Tigers Tale

Look at PetVivo, Inc. (OTCQB: PETV)

203

PetVivo, Inc. (OTCQB: PETV), is the producer of “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses is intended to provide a lubricious cushion between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.

Recently Dana Westerman, a veterinarian at the Seattle Zoo shared a story about a Tiger’s “tale” in a recent documentary about its flagship product Kush, narrated by John Dolan, a managing member of PetVivo, Inc. (OTCQB: PETV) and Tracy Turner, DVM (Doctor of Veterinary Medicine). 

You can download a copy of the video here: 

https://www.dropbox.com/scl/fi/h9dx0q12newkxtccbe06l/Presentation_2020.mp4?dl=0&oref=e&r=ABSzqt4Hey9D4f_gzmg6ohi0emtk-2cvfYY9Dq5WMoKcUiFbu7z7peBAanEyMEMD4D2hGU7OvdO1df-9uDHDg656E17YQSXFFiwpNoApmGgAjfXJbICiPOH-zjKralDc5NFIpgT3CeLvzVvKjPURFCJPTS2ipU1jcbkUKd2jKBenDYjtVemVmp48tqqlJ5KgWm8&sm=1

A tiger at Dr. Westerman’s zoo had been licking his tail incisively bald, and an x-ray confirmed evidence of arthritis.  Dr. Westerman, the veterinarian anesthetized the tiger, took some radiographs, placed the needles radiographically and injected Kush in four joints of his tail. Subsequently, the tiger’s hair began to grow back, and he is no longer licking his tail.  

Prior to this, Dr. Westerman had tried laser therapy by working on the tail outside of his cage with the laser. With anesthesia being an issue, she wanted to find a solution that she did not have to repeat.  

Kush is made from all-natural materials; collagen elastin and heparin, lasts for 12 months or longer and can be repeated each year.

Dr. Westerman also had great success with a horse that one of her veterinary clients had adopted which developed a torn stifle meniscus, and the prior owner of the horse spent a great deal of money on treatments but had eventually had thrown in the towel and advised euthanasia.  Dana initially tried stem cells, followed by Kush.  A few months later when Dana went to re-visit the horse, she found him trotting around and thought it was a completely different horse. 

Kush is expected to launch in Q1 2021, with sales in the $4.8 billion dog and horse therapeutics market, and Petvivo (OTCQB: PETV) currently has 17 products in its pipeline. 

Currently manufacturing commercializing and licensing innovative medical devices and therapeutics for companion animals, PetVivo, Inc. (OTCQB: PETV) is Emerging Biomedical device company located in Minneapolis Minnesota.

The company originally began with a group of innovative individuals from the medical device industry developing human based products with an attempt to leverage the human based therapies into the companion market. 

Receiving his DVM degree from Colorado State University in 1978, Tracy Turner went on to an internship at the University of Georgia and further to achieve a Master of Science degree at Perdue University in 1981. Dr. Turner is the founder of Turner Equine Sports Medicine and Surgery. 

Kush treats the root cause of a joint affliction, such as the loss of cartilage in a way that does not treat the symptoms but treats the affliction itself. Kush acts like a small sponge when put into the joint, which fills in the gaps or loss of cartilage, creating a cushion between the bones and preventing bone on bone contact. 

Originally made for the cosmetics market, Kush was originally introduced to Dr. Turner 10 years ago where he was invited to try the injection in a horse’s foot, and subsequently, after astonishing results tried the injection in other joints that he had worked with.  Dr. Turner has gone on to try other products in the space but to put in his words “Kush is better because it’s all natural”.  

In June of 2018, Dr. Turner was added to PetVivo’s advisory board. 

In the presentation, Dr. Turner recalls a horse with an injured meniscus that was no longer responsive to any other therapy.  As a last resort, he injected the horse with Kush, and at his follow up appointment two weeks later, Dr. Turner was so amazed at the results that he thought the owner switched horses on him.  

PetVivo Holdings, Inc. made a name for itself when a new successful Kush study came to light when Fender Bender, a racehorse suffering from osteoarthritis, was put up for sale and claimed for $3,000.00 and the new owner treated him with PetVivo’s Kush.  Fender Bender won at Canterbury Park on August 4, 2020. 

The product is easy to use and a a great product for vets because of its relatively inexpensive cost and high margins. 

PetVivo Holdings, Inc. (OTCQB: PETV) recently showed off at the AAEP (American Association of Equine Partitioners) Virtual Convention and Trade show from December 5th through December 8th, and the investment community was obviously appreciating it.  AAEP is the largest veterinary equine conference in the United States and hosted many of the top industry professionals. 

PetVivo met with many of the more than 1,000 participants to introduce its lead product, KUSH, a medical device injection of sterilized, hydrogel microparticles that are wet, slippery and spongy used in the treatment of lameness and other joint related afflictions, such as osteoarthritis. 

In addition to what they are showing off at the AAEP convention, The company just announced a sponsored research agreement with Colorado State University (“CSU”) College of Veterinary Medicine and Biomedical Sciences to engage in a clinical study involving the treatment of osteoarthritis in canines through the administration of PetVivo’s proprietary medical device, KUSH

PetVivo Holdings, Inc. (OTCQB: PETV) also recently announced that a company out of Orlando, Florida called nScrypt that designs and manufactures high-precision industrial Micro-dispensing and Direct Digital Manufacturing equipment, has just successfully 3D bio-printed PetVivo’s (OTCQB: PETV) biomaterial for orthopedic implants using its Bio-Fabrication Tool (BAT). To the best of the company’s knowledge, there is no other company that has the ability to provide these life-based components for the 3D printing marketplace.

Should it be a surprise that we learned just recently in the company’s 8-K that PetVivo Holdings, Inc. (OTCQB: PETV) adopted and approved an amended and restated “Charter of the Audit Committee”, “Charter of the Compensation Committee” and a “Nominating and Corporate Governance Committee Charter?”  All of which are required by NASDAQ

Audit Committee:

            PetVivo Holdings’ Audit Committee will consist of three or more directors and each committee member will, among other requirements, qualify as an independent director, and at least one of them will qualify as an “audit committee financial expert”, all also as required by NASDAQ Rules. 

Compensation Committee:

            PetVivo Holdings’ Compensation Committee will consist of two or more directors and each committee member will, among other requirements be independent in accordance with the NASDAQ Rules. 

Nominating and Corporate Governance Committee:

            PetVivo Holdings’ Nominating and Corporate Governance Committee will consist of two or more directors and each committee member will qualify as an independent director in accordance with the rules of the NASAQ Stock Market. 

See page 11 of the “Nasdaq Official Listing Guide of June 2020

With regard to nScrypt, the applications and cures for this technology are endless.  Implants, replacements, up until and including the present, have been made with foreign ingredients like titanium and other metals.  The future of this science now lies with the technology that allows for a more biologically familiar biomaterial.  PetVivo’s biomaterial is made from the same components as the body’s natural tissue, allowing cells to be added to the structures being printed.  

Ultimately, this breakthrough could lead to the creation of implants that actually mimic the bone itself.

Currently PetVivo Holdings, Inc. (OTCQB: PETV) has only 26 million shares outstanding and a market cap of $76 million according to OTCMarkets

Back in July, Marble Arch Research stated (You can download the full report here:) – among other results, “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”

Goldman Research just announced a new report with its current target price under review.  You can see the report here:Pet Vivo (OTCQB: PETV) also has a portfolio of 19 patents that protect the company’s pipeline of 16 products for the treatment of animals and people. 

About EmergingGrowth.com

Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated nine thousand one hundred dollars in consideration for its work with PetVivo Holdings, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here, https://emerginggrowth.com/68372-7388/.  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.